Diakonos Gains FDA Fast Track for DOC1021 Melanoma
HOUSTON, May 6, 2026 Diakonos Oncology Corp., a clinical-stage biotechnology company focused on next-generation cancer immunotherapies, has announced that...
Cancer Immunotherapy
Advertisement
OS Therapies Secures EMA Review for OST-HER2 Drug
NEW YORK, New York, April 30, 2026 OS Therapies announced that the European Medicines Agency (EMA) has initiated a...
EnGeneIC Doses First Patient in GBM EDV Therapy Trial
SYDNEY, AUSTRALIA, May 01, 2026 EnGeneIC has announced a critical clinical milestone with the first patient dosed in its...
Scancell Advances Cancer Immunotherapy Pipeline Momentum
OXFORD, UK, April 28, 2026 Scancell Holdings plc, a clinical-stage biopharmaceutical company specializing in cancer immunotherapies, has reported significant...
Citius Oncology Drives LYMPHIR Adoption in Cancer Care
CRANFORD, N.J., March 31, 2026 Citius Oncology, Inc. has reported strong early momentum following the U.S. launch of its...
Advertisements
OS Therapies Advances OST-HER2 Toward FDA Approval
NEW YORK, March 31, 2026 — OS Therapies, Inc a clinical-stage oncology company specializing in listeria-based cancer immunotherapies, has...
CStone CS2009 Shows Strong Phase I/II Cancer Data
Suzhou, China – March 26, 2026 CStone Pharmaceuticals announced significant clinical progress for its trispecific antibody CS2009, highlighting strong...
Incyte’s Zynyz Approved in EU for Advanced Anal Cancer
March 06, 2026 — Wilmington, Delaware, USA Global biopharmaceutical innovator Incyte has announced that the European Commission has approved...
Johnson & Johnson Wins FDA Approval for Tecvayli–Darzalex Myeloma Therapy
HORSHAM, Pennsylvania – March 5, 2026 Johnson & Johnson announced that the U.S. Food and Drug Administration has approved...
FDA Clears Scancell IND for Phase 3 iSCIB1+ Melanoma Trial
Cambridge, United Kingdom, January 26, 2026 — Scancell Holdings plc announced on January 26, 2026, that the U.S. Food...
Advertisement
